A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
- 25 February 2017
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 38 (5), 427-437
- https://doi.org/10.1016/j.tips.2017.02.001
Abstract
No abstract availableKeywords
Funding Information
- Frederick National Laboratory for Cancer Research, National Institutes of Health (NIH) (HHSN261200800001E)
This publication has 90 references indexed in Scilit:
- Converting Cancer Therapies into Cures: Lessons from Infectious DiseasesCell, 2012
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancerNature Chemical Biology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalThe EMBO Journal, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002